2021
What makes the psychosis ‘clinical high risk’ state risky: psychosis itself or the co-presence of a non-psychotic disorder?
Hasmi L, Pries L, Have M, de Graaf R, van Dorsselaer S, Bak M, Kenis G, Richards A, Lin B, O'Donovan M, Luykx J, Rutten B, Guloksuz S, van Os J. What makes the psychosis ‘clinical high risk’ state risky: psychosis itself or the co-presence of a non-psychotic disorder? Epidemiology And Psychiatric Sciences 2021, 30: e53. PMID: 34225831, PMCID: PMC8264801, DOI: 10.1017/s204579602100041x.Peer-Reviewed Original ResearchConceptsNon-psychotic disordersClinical high-risk stateClinical high riskHigh-risk stateHigh riskPsychotic symptomsPsychotic experiencesProspective general population cohortEarly psychotic experiencesIncident psychotic experiencesGeneral population cohortHealth service usePsychosis risk statesDrug use disordersPositive family historySchizophrenia polygenic risk scoresPsychosis incidenceAntipsychotic medicationYearly incidenceFamily historyPolygenic risk scoresRisk scoreAPS researchPRS-SZService use
2016
Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications. FOCUS The Journal Of Lifelong Learning In Psychiatry 2016, 14: 370-377. PMID: 31997958, PMCID: PMC6988756, DOI: 10.1176/appi.focus.140308.Peer-Reviewed Original Research
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees
2010
P03-343 - Treatment choice in psychiatry? How would European trainees treat psychosis for their patients and themselves, and what influences decision-making?
Jauhar S, Guloksuz S, Marques J, Bendix M, Lydall G, Andlauer O, Gerber S, Roventa C, Van Zanten J, De Vriendt N, Nawka A, Nwachukw I, Dobrzynska E, Mufic A, Nazaraliev A, Dumitrescu I, Mendonca L, Riese F, Group E. P03-343 - Treatment choice in psychiatry? How would European trainees treat psychosis for their patients and themselves, and what influences decision-making? European Psychiatry 2010, 25: 958. DOI: 10.1016/s0924-9338(10)70949-4.Peer-Reviewed Original ResearchFirst-line therapySide effect profileTreatment choiceClinical practicePsychiatric clinical practiceEuropean traineesCATIE trialAntipsychotic medicationAntipsychoticsResponse ratePatientsEvidence baseMinimum response ratePsychosisRecent evidenceClozapineTherapyEfficacySample sizeTraineesPsychiatryMedicationsPrescribingFactorsResponders